Severe Acute Respiratory Syndrome Coronavirus 2 Evolution and Escape From Combination Monoclonal Antibody Treatment in a Person With HIV

Dara Khosravi; Hannah Soloff; Rose M Langsjoen; Andrei Bombin; Colleen F Kelley; Susan M Ray; Clifford J Gunthel; Brian C Zanoni; Phuong-Vi Nguyen; Jesse J Waggoner; Yun F Wang; Valeria D Cantos; Anne Piantadosi

doi:10.1093/ofid/ofad054

Severe Acute Respiratory Syndrome Coronavirus 2 Evolution and Escape From Combination Monoclonal Antibody Treatment in a Person With HIV

Open Forum Infect Dis. 2023 Feb 3;10(2):ofad054. doi: 10.1093/ofid/ofad054. eCollection 2023 Feb.

Authors

Affiliations

¹ Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
² Emory University, Atlanta, Georgia, USA.
³ Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
⁴ Children's Healthcare of Atlanta, Atlanta, Georgia, USA.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) escape from combination monoclonal antibody treatment is rarely reported. We describe an immunocompromised individual with human immunodeficiency virus and persistent SARS-CoV-2 infection in whom substantial SARS-CoV-2 evolution occurred, including the emergence of 2 mutations associated with escape from the monoclonal antibody cocktail received.

Keywords: HIV; SARS-CoV-2; immunocompromised; monoclonal antibody; virus evolution.